Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
1°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
3.590
-0.010 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Xeris to Participate in Upcoming Investor Conferences
February 05, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
January 10, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Xeris Biopharma
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
May 06, 2024
Via
ACCESSWIRE
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in Upcoming Investor Conferences
August 22, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
May 09, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
February 28, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
February 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
January 10, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Updates Its Outlook for 2023
January 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
